Philippe Ngo Van

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

Jean‐François Delfraissy, Philippe Flandre, Constance Delaugerre et al. · AIDS · 2008 · 137 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

Constance Delaugerre, Philippe Flandre, Marie‐Laure Chaix et al. · Antimicrobial Agents and Chemotherapy · 2009 · 54 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

High Prevalence and Impact on the Quality of Life of Facial Lipoatrophy and Other Abnormalities in Fat Tissue Distribution in HIV-Infected Patients Treated with Antiretroviral Therapy

Pascale Leclercq, Cécile Goujard, Martin Duracinský et al. · AIDS Research and Human Retroviruses · 2012 · 34 citations

Public Health, Pharmacotherapy, Dermatopathology +10

Prospective one-year bone loss in treatment-naïve HIV+ men and women on single or multiple drug HIV therapies

Karine Briot, S. Kolta, Philippe Flandre et al. · Bone · 2011 · 23 citations

Medicine, Orthopedic Surgery, Bone Metabolism +14

Fat Tissue Distribution Changes in HIV-Infected Patients Treated with Lopinavir/Ritonavir. Results of the MONARK Trial

S. Kolta, Philippe Flandre, Philippe Ngo Van et al. · Current HIV Research · 2011 · 20 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17